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Manuscript rece1977, the World Health Organization (WHO) developed its ﬁrst Model List of Essential Medicines to guide
countries in the creation of national formularies and policies for access, quality, and use of essential medicines as
part of achieving the right to health. In 2012, the WHO announced its goal of reducing the number of premature
deaths (<70 years) due to noncommunicable chronic diseases by 25% by the year 2025, including the indicator that
50% of eligible people receive drugs to prevent myocardial infarction and stroke. Despite the large body of evidence
supporting the use of pharmacological treatment for the secondary prevention of cardiovascular diseases (CVD),
substantial gaps in coverage of secondary interventions for prevention of CVD are widespread globally. Fixed dose
combination, or polypill, therapy has been shown to improve adherence by 33% compared with usual care in CVD
secondary prevention and has been recommended as a “best buy” by the WHO. In November 2012, along with
5 other scientists, we submitted an application to the Model List of Essential Medicines to include polypill therapy for
secondary CVD prevention. In July 2013, the updated 18th Model List of Essential Medicines was released without
inclusion of polypill therapy for secondary CVD prevention. In this article, we argue that polypill therapy meets
the criteria for essential medicines and that inclusion in the Model List of Essential Medicines will facilitate its
access and has the potential to avoid a few million premature deaths and related morbidity from CVD at low cost.
(J Am Coll Cardiol 2014;63:1368–70) ª 2014 by the American College of Cardiology FoundationBackground to the World Health Organization
Model List of Essential Medicines
Access to essential medicines is considered an integral
component of the “universal right to the highest attainable
standard of health” according to the World Health Orga-
nization (WHO) constitution (1946) (1). Medicines deﬁned
as essential are “those that satisfy the priority health care
needs of the population based on disease prevalence, evi-
dence on safety and efﬁcacy and comparative cost effec-
tiveness” (2). In 1977, the WHO developed its ﬁrst Model
List of Essential Medicines to guide countries in the crea-
tion of national formularies and policies for access, quality,
and use of essential medicines as part of achieving that right.
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“available within the context of functioning health systems at
all times in adequate amounts, in the appropriate dosage
forms, with assurance quality, and at a price the individual
and community can afford” (2). Despite the declaration and
acceptance of this right by the international community for
more than 35 years, access to essential medicines remains
low. In a 2009 analysis of 36 low- and middle-income
countries, access to essential medicines for prevention and
control of noncommunicable chronic diseases (NCDs) was
limited to 36% and 55% in public and private sectors,
respectively, compared with 54% and 66% that had access to
medications for acute diseases, respectively (3).WHO “25 3 25” Goal
In 2012, the WHO announced its goal of reducing the
number of premature deaths (<70 years) due to NCDs by
25% by the year 2025 (4). This target was preceded by other
WHO goals of reducing the burden of premature death and
of disability from NCDs, which were formalized as a result
of the Political Declaration from the 2011 United Nations
High Level Meeting on NCDs. Because cardiovascular
diseases (CVD) are the leading causes of mortality in the
world and because more than 80% of CVD deaths occur in
low- and middle-income countries, CVD treatment and
control are crucial for reaching these WHO goals. If current
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1369trends continue, CVD morbidity and mortality are projected
to increase substantially in the coming decades. The CVD
secondary prevention with ﬁxed-dose combination, or pol-
ypill, therapy has been deemed a “best buy” by the WHO
(5), given its efﬁcacy, adherence, scalability, and cost-
effectiveness. More than one-half of patients with prior
ischemic heart disease or stroke receive no secondary med-
ications, and <10% receive all 3 of the 4 proven medications
(antiplatelet agents, statins, beta-blockers, and blood pres-
sure–lowering drugs) (6). This situation is much worse in
low-income countries, where more than 3 of every 4 patients
with CVD take zero medications (6). Yet the WHO recent
indicators to reach its “25  25” target include the provision
that 50% of eligible people receive drugs to prevent
myocardial infarction and stroke.
A large amount of evidence supports the use of pharma-
cological treatment for the secondary prevention of cardio-
vascular death in patients with prior CVD events.
Antiplatelet agents, beta-blockers, lipid-lowering agents,
and angiotensin-converting enzyme inhibitors have all
individually demonstrated improvements in mortality and
morbidity and are recommended for secondary prevention of
CVD by a diverse group of professional organizations.
However, substantial gaps in coverage of secondary in-
terventions for prevention of CVD are widespread globally
(6). There are numerous reasons for these substantial gaps,
which include lack of their value and the importance of
lifelong therapy perceived by both physicians and patients,
lack and costs of access to health practitioners, lack of
availability (stock-outs) of key medications, poor adherence,
unaffordable costs of even generic drugs compared with local
incomes, and inadequate prescription of medicines. Fixed-
dose combination therapy that combines CVD secondary
preventive medicines seems to overcome many of these
barriers. In particular, ﬁxed-dose combination therapy has
been shown to improve adherence by 33% compared with
usual care in CVD secondary prevention (7), thus meeting
the Model List recommendation that ﬁxed-dose combina-
tion therapies should have “a proven advantage in thera-
peutic effect, safety or compliance over single compounds
administered separately” (2). Furthermore, ﬁxed-dose com-
binations can be less expensive, thereby making them more
affordable.
Fixed-Dose Combination, or Polypill, for Secondary
CVD Prevention as an Essential Medicine?
In November 2012, we and 5 scientists submitted an appli-
cation with support from 51 colleagues from 19 countries to
the WHO 18th Expert Committee on the Selection and Use
of Essential Medicines to recommend that ﬁxed-dose com-
bination, or polypill, therapy be added to the WHO Model
List of Essential Medicines for the secondary prevention of
CVD (ischemic heart disease and thrombotic stroke). Our
application was not accepted on the basis of the recom-
mendations from 2 expert reviewers, 1 of whom suggestedthat the “Committee needs to
decide whether it is willing to
make a largely symbolic gesture
now, by including one or all
of the proposed combinations,
while knowing that global access
will be slow and that sufﬁcient
evidence of efﬁcacy, safety and
cost-effectiveness are not as yet at
hand” (2).
Although ﬁxed-dose combination therapy per se has not
been tested for efﬁcacy in secondary prevention of CVD,
each of the components has individually demonstrated
reduction of mortality and morbidity when given against a
background of other proven drugs. Therefore, the beneﬁts of
the drugs are additive, and all 4 are recommended by
numerous guidelines to be used together. However, these
medicines individually and when used in combination have
also been shown to be well tolerated. Recent trials indicate
that ﬁxed-dose combination therapy reduces lipid levels
(through which statins are thought to exert their beneﬁcial
effects) and blood pressure (a marker of the effects of
angiotensin-converting enzyme inhibitors, beta-blockers,
and diuretics) to the same extent as giving each drug sepa-
rately (an additive effect on the surrogate markers of efﬁ-
cacy), the effects of aspirin on suppression of markers of
thromboxane A2 are similar when it is given separately or in
combination with the other components of the polypill, and
they are well-tolerated (8). Similar or improved efﬁcacy,
tolerance, and adherence have been demonstrated both in
individuals with prior CVD (compared against the indi-
vidual components given separately) (7) and in individuals
without prior CVD (compared against placebo) (8).
Furthermore, the efﬁcacy of ﬁxed-dose combination therapy
with other medicines has been demonstrated in populations
of patients with other conditions such as acquired immune
deﬁciency syndrome, tuberculosis, and hypertension, thereby
supporting the general concept that using drugs in ﬁxed-dose
combinations has merit.
Each individual component of ﬁxed-dose combination
therapy for CVD prevention has been proven to reduce
death, myocardial infarction, or stroke in patients with
ischemic heart disease or stroke. The existing data on ﬁxed-
dose combination therapy show the combinatorial formu-
lation reduces risk factors to the extent expected if the
components were given individually (8–10). Therefore, the
current consensus is that the ﬁxed-dose combination therapy
should be considered for use in CVD secondary prevention.
This conclusion is based on the existing data and the high-
risk proﬁle for CVD events in patients eligible for secondary
prevention.
Conclusions
Approval for inclusion of the polypill will not just be a
symbolic gesture. Instead, it will emphasize to a broad set of
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1370stakeholders the beneﬁts of combination therapy; it could
stimulate pharmaceutical manufacturers to commit the
necessary resources to develop and test various polypills, and
equally importantly, it would encourage regulators in being
more ﬂexible in developing a practical pathway to approvals
of a polypill. Inclusion of ﬁxed-dose combination therapy in
the Model List of Essential Medicines will facilitate its ac-
cess and has the potential to avoid a few million premature
deaths and related morbidity from CVD at low cost. Fixed-
dose combination therapy meets the aforementioned criteria
for essential medicines, namely priority health care need,
safety, efﬁcacy, and cost-effectiveness, and should be
included in the WHOModel List of Essential Medicines as
part of a comprehensive effort to help achieve the WHO
“25  25” goal.
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